Asan Medical Center and Yonsei University Research Team
Isolation of Brain Cell-Derived Nanoparticles from Blood Using Nanotechnology
"Further Large-Scale Patient Validation Planned to Clarify Clinical Applicability"

A technology that can detect brain cell damage signals through a simple blood test and track the activity of brain diseases has been developed by a Korean research team. This raises the possibility of utilizing it as a biomarker to monitor disease progression without repeated MRI scans.

(From left) Eunjae Lee, Professor of Neurology at Asan Medical Center, Jinhee Kim, PhD at the Institute for Biomedical Research, Yong Shin, Professor of Biotechnology at Yonsei University, Yeonjeong Noh and Hyoju Lee, Researchers at Yonsei University. Asan Medical Center

(From left) Eunjae Lee, Professor of Neurology at Asan Medical Center, Jinhee Kim, PhD at the Institute for Biomedical Research, Yong Shin, Professor of Biotechnology at Yonsei University, Yeonjeong Noh and Hyoju Lee, Researchers at Yonsei University. Asan Medical Center

View original image

Asan Medical Center announced on March 10 that the research team led by Professor Eunjae Lee of the Department of Neurology and Dr. Jinhee Kim at the Institute for Life Sciences, in collaboration with the research team of Professor Yong Shin from the Department of Biotechnology at Yonsei University, has developed a nanotechnology that selectively isolates only specific brain cell-derived extracellular vesicles from blood. The research findings were recently published in the international journal 'Nano Today.'


Extracellular vesicles are tiny vesicles secreted by cells that contain various biological information such as proteins and microRNAs. Recently, it has been revealed that brain-derived extracellular vesicles can pass through the blood-brain barrier and move into peripheral blood, prompting research into assessing brain condition via blood samples. However, since the blood contains vesicles originating from various cells, there has been a limitation in isolating signals from only specific brain cells.


To address this, the research team developed the EPIN (Extracellular vesicle Peptide-Imprinted Nanocomposite) technology. This approach mimics specific protein structures to selectively recognize target molecules. By designing it to recognize astrocyte surface proteins, only astrocyte-derived vesicles among extracellular vesicles in the blood can be isolated. The separation process is completed within about 40 minutes.


To confirm the clinical applicability of this technology, the research team analyzed serum samples from patients with neuromyelitis optica spectrum disorder. This autoimmune disease attacks astrocytes, leading to repeated relapses and potentially accumulating neurological disabilities, making the assessment of disease activity crucial.


Analysis of 147 serum samples stored at the Asan Medical Center Biobank revealed that relapsed patients had higher levels of glial fibrillary acidic protein (GFAP) compared to patients in a stable phase. In contrast, aquaporin-4 immunoglobulin G (AQP4-IgG), a known diagnostic marker for the disease, tended to decrease in relapsed patients. The research team explained that this marker reflected relapse status regardless of patient age or degree of neurological disability.


Furthermore, when analyzing serum samples from patients with multiple sclerosis and Parkinson's disease, different molecular patterns were observed for each disease, confirming the possibility of differential diagnosis. Characteristic changes in microRNA signals inside extracellular vesicles were also observed during relapse phases.


The research team believes that if blood-based biomarkers are applied in clinical settings, they could reduce the burden of repeated imaging tests and be used to evaluate treatment response or establish personalized treatment strategies.


Professor Lee stated, "This research presents the possibility of tracking brain changes through blood tests alone," and added, "We plan to conduct further validation with a large patient cohort to confirm clinical applicability."



This study was supported by the Korea Health Industry Development Institute's project for developing diagnostic technologies for rare diseases and the National Research Foundation of Korea's mid-career researcher program.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing